<Home> <Newsletter> <Third Issue> <Antivirals for H1N1 Infection> <Antiviral Drugs: Summary of Side Effects>


Issue No. 003/09

20 November2009

 
Main Topic: H1N1 FLU (SWINEFLU)

ANTIVIRALS FOR H1N1 INFECTION

Antiviral Drugs: Summary of Side Effects

Amantadine and Rimantadine

Among some healthy adults and children, side effects can include central nervous system (CNS) side effects such as nervousness, anxiety, difficulty concentrating, and lightheadedness, and gastrointestinal side effects like nausea and loss of appetite. CNS side effects happen more often among persons taking amantadine than among persons taking rimantadine. Among some other persons with long-term illnesses, more serious side effects, such as delirium, hallucinations, agitation, and seizures, can occur. Side effects usually diminish and disappear after 1 week.

Zanamivir

This drug is inhaled and can cause side effects, especially in those with asthma or other chronic lung disease. Decreased respiratory function and bronchospasm have been reported with use of zanamivir. Zanamivir is generally not recommended for use in persons with underlying lung disease such as asthma and chronic obstructive pulmonary disease. Other side effects reported by less than 5% of those who have used this drug are diarrhea, nausea, sinusitis, nasal infections, bronchitis, cough, headache, and dizziness.

Oseltamivir

The side effects reported most often in those people who took this drug were gastrointestinal (i.e., nausea and vomiting). Nausea and vomiting may be less severe if oseltamivir is taken with food.

Note: On November 13, 2006, FDA approved a labeling supplement for Roche Laboratories’ Tamiflu (Oseltamivir Phosphate) to include a precaution about neuropsychiatric events. The revision is based on postmarketing reports (mostly from Japan) of self-injury and delirium with the use of Tamiflu in patients with influenza. The reports were primarily among pediatric patients. The relative contribution of the drug to these events is not known. However, people with the flu, particularly children, may be at an increased risk of self-injury and confusion shortly after taking Tamiflu and should be closely monitored for signs of unusual behavior. A healthcare professional should be contacted immediately if the patient taking Tamiflu shows any signs of unusual behavior.

Visit http://www.fda.gov/medwatch/safety/2006/safety06.htm#tamiflu for more information.

 
IOMS Newsletter - 20 November 2009  
Issue No. 003/09
 
 
Back to Main Page (Contents) Back to Main Page (Contents)

Islamset Homepage